Stockreport

Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates

Genelux Corporation  (GNLX) 
PDF -- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected [Read more]